[Form 4] Intellia Therapeutics, Inc Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview: On 07/02/2025, Chief Executive Officer Michael Heltzen reported an open-market purchase (transaction code “P”) of 1,040 shares of Exozymes Inc. (ticker EXOZ) common stock at a price of $10.22 per share. Following the transaction, Heltzen’s direct beneficial ownership increased to 10,628.8 shares. No derivative securities transactions were reported, and the filing was submitted individually (not jointly).

The purchase represents a modest addition to the CEO’s holdings and is the earliest reportable transaction for the period. Because the form lists no sales or derivative exercises, it signals a net increase in insider ownership.

Positive

• CEO insider purchase: Acquisition of 1,040 shares at $10.22 suggests management confidence and aligns interests with shareholders.

Negative

• Small transaction size: The ~$10.6k purchase is unlikely to materially affect ownership concentration or signal significant strategic change.

Insights

Securities Analyst

TL;DR Small CEO share purchase; positive signal but immaterial to fundamentals and trading liquidity.

Detail: A 1,040-share acquisition at $10.22 totals roughly $10.6k, raising the CEO’s stake to 10.6k shares. Insider buying, especially by a CEO, is directionally positive because it aligns management with shareholders and can indicate confidence in near-term prospects. However, the dollar value is minimal relative to typical executive compensation and the company’s likely market capitalization, limiting market impact. No options, warrants, or other derivatives were involved, so there is no implied leverage or dilution consequence. Overall, the filing is noteworthy for governance watchers but not materially impactful for valuation models or liquidity considerations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOODMAN JESSE

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		S(1)		1,547	D	$9.56	25,906	D
Common Stock	07/01/2025		S(1)		1,547	D	$9.23	24,359	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sale of 3,094 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 31, 2025.

	/s/ James Basta, attorney-in-fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Exozymes (EXOZ) shares did CEO Michael Heltzen buy?

He purchased 1,040 common shares on 07/02/2025.

What price did the CEO pay for the EXOZ shares?

The shares were acquired at $10.22 per share.

What is Michael Heltzen’s total direct holding after the transaction?

Following the purchase, he owns 10,628.8 shares directly.

Was this Form 4 filed as part of a Rule 10b5-1 plan?

The filing does not indicate use of a Rule 10b5-1(c) trading plan.

Were any derivative securities reported in this Form 4?

No, the Table II section shows no derivative securities transactions.

Is the filing made solely by one reporting person?

Yes, the form is marked "Form filed by One Reporting Person."